United States: Wilmerhale Serves As Counsel To Idera Pharmaceuticals In Public Offering Of Common Stock
Last Updated: November 10 2017

Idera Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 33,333,334 shares of its common stock at a public offering price of $1.50 per share. The company has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock. All of the shares in the offering are to be sold by Idera. The offering is expected to close on or about October 30, 2017, subject to customary closing conditions.

The WilmerHale team representing Idera in this transaction includes Stuart Falber, Ryan MittenessCaroline Dotolo and Jared Iverson.

View the press release.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Frédéric Louis, Christian Duvernoy, Dr. Martin Braun, D. Reed Freeman, Jr., Itsiq Benizri
By Frédéric Louis, Christian Duvernoy, Dr. Martin Braun, D. Reed Freeman, Jr., Itsiq Benizri
By Naboth van den Broek, David S. Cohen, Ronald Meltzer, David Horn, Frédéric Louis, Georgia Tzifa
By Steven Finizio
By Chris Postizzi WilmerHale
By Lloyd Firth
By Mark Ford, Peter Spaeth, Holly Ovington
By Chris Postizzi WilmerHale
By Gregory Lantier, Brittany Amadi
By Anna Gaudoin
Tools
Print
Font Size:
Translation
Channels